The results in this work are supported by the recent demonstration that breast tumour-bearing mice treated with ICRP present a decrease in tumour volume and increase in survival in comparison with untreated mice.63 Also, within the tumour, ICRP treatment decreased PD-L1, IDO and Gal-3 expression, IL-6, IL-10 and MCP-1 levels, and increased IFN-γ and IL-12 levels. This evidence concerns the gene CD274 and neoplasm.